78P Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+ GC) in patients (pts) with advanced biliary tract cancer (BTC)

D-Y Oh,J.W Kim,M Kitano,A.R He,T Okusaka,A Avallone,S Tanasanvimon,J.E Cundom,N Rokutanda,A Vogel,J.W Valle,M Żotkiewicz,M.A Lee,T Lee,G Cohen,M Bouattour,S Qin,H.A Burris,R.E Zaucha,Chen Lt

doi:10.1016/j.annonc.2022.10.114

78P Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+ GC) in patients (pts) with advanced biliary tract cancer (BTC)

D-Y Oh, J.W Kim + Show 18 more

Open Access

https://doi.org/10.1016/j.annonc.2022.10.114

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Nov 1, 2022
Citations: 12	License type: publisher-specific-oa

Affiliation: Seoul National University Hospital

#Advanced Biliary Tract Cancer #Preplanned Interim Analysis + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Advanced BTC is a rare, heterogenous cancer with poor prognosis. At the preplanned interim analysis (data cutoff 11 August 2021) of TOPAZ-1 (NCT03875235), D + GC significantly improved OS versus PBO + GC in pts with advanced BTC (hazard ratio [HR], 0.80; 95% confidence interval [CI], 0.66–0.97; p=0.021). We report an updated OS and safety analysis for TOPAZ-1.

Full Text